901 research outputs found
Waiting list trends for liver transplantation in Italy: A snapshot from the future
No full textNo abstrac
Hepatitis C virus post-exposure prophylaxis: A reasonable option in the era of pangenotypic direct-acting antivirals?
No full textMicro-elimination of hepatitis C virus infection in β-Thalassaemia major patients: Positively moving towards the World Health Organisation 2030 eradication goal
No full textSupplemental material for Safety of vedolizumab in liver transplant recipients: A systematic review
No full textSupplemental Material for Safety of vedolizumab in liver transplant recipients: A systematic review by Marco Spadaccini, Alessio Aghemo, Flavio Caprioli, Ana Lleo, Federica Invernizzi, Silvio Danese and Maria F Donato in United European Gastroenterology Journal</p
DAAHCVGNTablesIFNmodified – Supplemental material for Immunosuppressive and antiviral treatment of hepatitis C virus–associated glomerular disease: A long-term follow-up
No full textSupplemental material, DAAHCVGNTablesIFNmodified for Immunosuppressive and antiviral treatment of hepatitis C virus–associated glomerular disease: A long-term follow-up by Fabrizio Fabrizi, Alessio Aghemo, Pietro Lampertico, Mirella Fraquelli, Donata Cresseri, Gabriella Moroni, Patrizia Passerini, Francesca M Donato, Piergiorgio Messa in The International Journal of Artificial Organs</p
Hepatogenous diabetes. Is it time to separate it from type 2 diabetes?
No full textBy definition, hepatogenous diabetes is directly caused by loss of liver function, implying that it develops after cirrhosis onset. Therefore, it should be distinguished from type 2 diabetes developing before cirrhosis onset, in which specific causes of liver disease play a major role, in addition to traditional risk factors. Currently, although hepatogenous diabetes shows distinct pathophysiological and clinical features, it is not considered as an autonomous entity. Recent evidence suggests that the failing liver exerts an independent "toxic" effect on pancreatic islets resulting in β-cell dysfunction. Moreover, patients with hepatogenous diabetes usually present with normal fasting glucose and haemoglobin A1c levels and abnormal response to an oral glucose tolerance test, which is therefore required for diagnosis. This article discusses the need to separate hepatogenous diabetes from type 2 diabetes occurring in subjects with chronic liver disease and to identify individuals suffering from this condition for prognostic and therapeutic purposes
Management and Treatment of Hepatitis C: Are There Still Unsolved Problems and Unique Populations?
No full textDirect-acting antivirals (DAA) have revolutionized the treatment of patients with chronic hepatitis C virus (HCV) infection, possibly leading to HCV elimination by 2030 as endorsed by the World Health Organization (WHO). However, some patients belonging to the so-called unique or special populations are referred to as difficult-to-treat due to unreached sustained virological response, potential drug side effects or interactions or co-morbidities. Several years after the DAA introduction and on the basis of excellent findings in terms of efficacy and safety, some doubts arise around the exact meaning of the special population designation and whether this group of patients actually exists. The aim of this review is to discuss and analyze current evidence on the management and treatment of the so-called “unique populations”. We placed particular emphasis on patients with decompensated cirrhosis, chronic kidney disease (CKD), coinfections, rare genotypes, and previous treatment failure, in order to provide physicians with an updated overview of the actual problems and needs in the current scenario
Peginterferon maintenance therapy in patients with advanced hepatitis C to prevent hepatocellular carcinoma: The plot thickens
No full textMaintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C. Lok AS, Everhart JE, Wright EC, Di Bisceglie AM, Kim HY, Sterling RK, Everson GT, Lindsay KL, Lee WM, Bonkovsky HL, Dienstag JL, Ghany MG, Morishima C, Morgan TR; HALT-C Trial Group. Gastroenterology. 2011;140:840-9. Copyright (2011). Abstract reprinted with permission from the American Gastroenterological Association. http://www.ncbi.nlm.nih.gov/pubmed/21129375 Abstract: Background & Aims: Interferon reportedly decreases the incidence of hepatocellular carcinoma (HCC) in patients with chronic hepatitis C. The Hepatitis C Antiviral Long-term Treatment against Cirrhosis (HALT-C) Trial showed that 4 years of maintenance therapy with pegylated interferon (peginterferon) does not reduce liver disease progression. We investigated whether peginterferon decreases the incidence of HCC in the HALT-C cohort over a longer posttreatment follow-up period. Methods: The study included 1048 patients with chronic hepatitis C (Ishak fibrosis scores ≥3) who did not have a sustained virologic response (SVR) to therapy. They were randomly assigned to groups given a half-dose of peginterferon or no treatment (controls) for 3.5 years and followed up for a median of 6.1 (maximum, 8.7) years. Results: Eighty-eight patients developed HCC (68 definite, 20 presumed): 37 of 515 who were given peginterferon (7.2%) and 51 of 533 controls (9.6%; p = 0.24). There was a significantly lower incidence of HCC among patients given peginterferon therapy who had cirrhosis, but not fibrosis, based on analysis of baseline biopsy samples. After 7 years, the cumulative incidences of HCC in treated and control patients with cirrhosis were 7.8% and 24.2%, respectively (hazard ratio [HR], 0.45; 95% confidence interval [CI], 0.24-0.83); in treated and control patients with fibrosis, incidences were 8.3% and 6.8%, respectively (HR, 1.44; 95% CI, 0.77-2.69). Treated patients with a ≥2-point decrease in the histologic activity index, based on a follow-up biopsy, had a lower incidence of HCC than those with unchanged or increased scores (2.9% vs. 9.4%; p = 0.03). Conclusions: Extended analysis of the HALT-C cohort showed that long-term peginterferon therapy does not reduce the incidence of HCC among patients with advanced hepatitis C who did not achieve SVRs. Patients with cirrhosis who received peginterferon treatment had a lower risk of HCC than controls
A 13-day, interferon-free regimen for chronic hepatitis C genotype 1 patients : between fear and hope
No full textA rapid point-of-care test for the diagnosis of HCV infection : tipping the balance to screening extension beyond high risk populations?
No full text- …
